Standard Biotools Stock Performance
| LAB Stock | USD 1.07 0.02 1.90% |
The entity has a beta of 1.06, which indicates a somewhat significant risk relative to the market. Standard Biotools returns are very sensitive to returns on the market. As the market goes up or down, Standard Biotools is expected to follow. At this point, Standard Biotools has a negative expected return of -0.81%. Please make sure to validate Standard Biotools' treynor ratio, skewness, and the relationship between the jensen alpha and value at risk , to decide if Standard Biotools performance from the past will be repeated at some point in the near future.
Risk-Adjusted Performance
Very Weak
Weak | Strong |
Over the last 90 days Standard Biotools has generated negative risk-adjusted returns adding no value to investors with long positions. Despite weak performance in the last few months, the Stock's basic indicators remain somewhat strong which may send shares a bit higher in April 2025. The current disturbance may also be a sign of long term up-swing for the company investors. ...more
1 | Ex-CNN pundit admits Trump was likely right about COVID-19 likely leaking from a lab | 01/28/2025 |
2 | Spatial Omics Research Report 2023-2034 Market to reach 1.09 Billion - 10x Genomics Enhances Spatial OMICS with New Visium Spatial Gene Expression for FFPE | 01/31/2025 |
3 | Acquisition by Casdin Partners Master Fund, L.p. of 250000 shares of Standard Biotools at 1.8529 subject to Rule 16b-3 | 02/10/2025 |
4 | Standard BioTools Schedules Fourth Quarter and Full Year 2024 Earnings Conference Call on ... | 02/12/2025 |
5 | NAVER D2SF Invests in STUDIO LAB, an AI-Powered E-Commerce Content Generation Startup | 02/14/2025 |
6 | Disposition of 31031 shares by Michael Egholm of Standard Biotools at 1. subject to Rule 16b-3 | 02/20/2025 |
7 | Market Cool On Standard BioTools Inc.s Revenues Pushing Shares 28 percent Lower | 02/21/2025 |
8 | Standard BioTools Inc Q4 2024 Earnings Report Preview What To Look For | 02/25/2025 |
9 | Standard BioTools GAAP EPS of -0.09 misses by 0.02, revenue of 46.72M beats by 3.69M | 02/26/2025 |
10 | Rove Lab Launches Modular Furniture Line with Focus on Sustainability and Accessibility | 02/27/2025 |
| Begin Period Cash Flow | 52.5 M |
Standard |
Standard Biotools Relative Risk vs. Return Landscape
If you would invest 194.00 in Standard Biotools on December 2, 2024 and sell it today you would lose (87.00) from holding Standard Biotools or give up 44.85% of portfolio value over 90 days. Standard Biotools is generating negative expected returns assuming volatility of 5.8144% on return distribution over 90 days investment horizon. In other words, 51% of stocks are less volatile than Standard, and above 99% of all equities are expected to generate higher returns over the next 90 days. Expected Return |
| Risk |
Standard Biotools Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Standard Biotools' investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as Standard Biotools, and traders can use it to determine the average amount a Standard Biotools' price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = -0.1395
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | ||||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns | LAB |
Estimated Market Risk
| 5.81 actual daily | 51 51% of assets are less volatile |
Expected Return
| -0.81 actual daily | 0 Most of other assets have higher returns |
Risk-Adjusted Return
| -0.14 actual daily | 0 Most of other assets perform better |
Based on monthly moving average Standard Biotools is not performing at its full potential. However, if added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Standard Biotools by adding Standard Biotools to a well-diversified portfolio.
Standard Biotools Fundamentals Growth
Standard Stock prices reflect investors' perceptions of the future prospects and financial health of Standard Biotools, and Standard Biotools fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Standard Stock performance.
| Return On Equity | -0.44 | ||||
| Return On Asset | -0.18 | ||||
| Profit Margin | (0.80) % | ||||
| Operating Margin | (0.29) % | ||||
| Current Valuation | 136.58 M | ||||
| Shares Outstanding | 372.26 M | ||||
| Price To Earning | (2.52) X | ||||
| Price To Book | 0.84 X | ||||
| Price To Sales | 2.27 X | ||||
| Revenue | 174.43 M | ||||
| Gross Profit | 21.85 M | ||||
| EBITDA | (175.24 M) | ||||
| Net Income | (138.88 M) | ||||
| Cash And Equivalents | 81.31 M | ||||
| Cash Per Share | 2.68 X | ||||
| Total Debt | 98.21 M | ||||
| Debt To Equity | 0.38 % | ||||
| Current Ratio | 5.87 X | ||||
| Book Value Per Share | 1.23 X | ||||
| Cash Flow From Operations | (143.45 M) | ||||
| Earnings Per Share | (0.52) X | ||||
| Market Capitalization | 396.46 M | ||||
| Total Asset | 323.07 M | ||||
| Retained Earnings | (1 B) | ||||
| Working Capital | 48.89 M | ||||
About Standard Biotools Performance
By analyzing Standard Biotools' fundamental ratios, stakeholders can gain valuable insights into Standard Biotools' financial health, operational efficiency, and overall profitability, helping them make informed investment and management decisions. For instance, if Standard Biotools has a high ROA and ROE, it suggests that the company is efficiently using its assets and equity to generate substantial profits, making it an attractive investment. Conversely, if Standard Biotools has a low ROA and ROE, it may indicate underlying issues in asset and equity management, signaling a need for operational improvements.
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | (0.31) | (0.33) | |
| Days Of Inventory On Hand | 154.21 | 197.10 | |
| Return On Capital Employed | (0.32) | (0.34) | |
| Return On Assets | (0.21) | (0.22) | |
| Return On Equity | (0.53) | (0.55) |
Things to note about Standard Biotools performance evaluation
Checking the ongoing alerts about Standard Biotools for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Standard Biotools help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Standard Biotools generated a negative expected return over the last 90 days | |
| Standard Biotools has high historical volatility and very poor performance | |
| Standard Biotools has some characteristics of a very speculative penny stock | |
| Standard Biotools has a very high chance of going through financial distress in the upcoming years | |
| The company reported the last year's revenue of 174.43 M. Reported Net Loss for the year was (138.88 M) with profit before taxes, overhead, and interest of 21.85 M. | |
| Standard Biotools has about 81.31 M in cash with (143.45 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 2.68, which can makes it an attractive takeover target, given it will continue generating positive cash flow. | |
| Standard Biotools has a frail financial position based on the latest SEC disclosures | |
| Roughly 73.0% of the company shares are owned by institutional investors | |
| Latest headline from finance.yahoo.com: Rove Lab Launches Modular Furniture Line with Focus on Sustainability and Accessibility |
- Analyzing Standard Biotools' financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Standard Biotools' stock is overvalued or undervalued compared to its peers.
- Examining Standard Biotools' industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Standard Biotools' management team can have a significant impact on its success or failure. Reviewing the track record and experience of Standard Biotools' management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Standard Biotools' stock. These opinions can provide insight into Standard Biotools' potential for growth and whether the stock is currently undervalued or overvalued.
Complementary Tools for Standard Stock analysis
When running Standard Biotools' price analysis, check to measure Standard Biotools' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Standard Biotools is operating at the current time. Most of Standard Biotools' value examination focuses on studying past and present price action to predict the probability of Standard Biotools' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Standard Biotools' price. Additionally, you may evaluate how the addition of Standard Biotools to your portfolios can decrease your overall portfolio volatility.
| Equity Valuation Check real value of public entities based on technical and fundamental data | |
| Odds Of Bankruptcy Get analysis of equity chance of financial distress in the next 2 years | |
| Idea Optimizer Use advanced portfolio builder with pre-computed micro ideas to build optimal portfolio |